Patients are highly satisfied with ritexitinib for the treatment of alopecia areata

Patients with hair loss who received Ritlecitinib reported higher levels of satisfaction than those who received a placebo, according to one study. Alopecia areata is a disease that causes hair loss in small or large areas of the scalp and/or body. Approximately 145 million people worldwide have AA, which occurs in children and adults. AA can have a big impact on a person's mental health and take a toll on self-esteem. AA can also cause feelings of worry or sadness. Therefore, it is important to understand whether people are satisfied with their AA treatment.

This analysis of patient-reported satisfaction includesALLEGRO Patients in clinical trial 2b/3, in which 718 patients with 50% or more scalp hair loss were randomly assigned to one of six arms: ritixitinib 10 mg daily (n=63), 30 mg daily (n=132) or 50 mg (n = 130); a 200 mg loading dose of rituxitinib, followed by a daily dose of 30 mg (n = 130) or 50 mg (n = 132); or placebo (n = 131) for 24 weeks.

A 24-week extension trial continued patients in the treatment group at their original dose and switched placebo-treated patients to a loading dose of 50 mg or 200 mg of ritixitinib daily, followed by 50 mg of ritixitinib for an additional 24 weeks.

Compared with placebo, a significantly higher proportion of patients in the treatment groups—particularly the high-dose treatment group—reported being mildly, moderately, or extremely satisfied at week 24, according to the researchers. Overall, 36.4% of patients in the 10 mg group and 67.5% of patients in the 50 mg group after the 200 mg loading dose reported some level of satisfaction. This compared to 22.6% in the placebo group. In the group that switched from placebo to the 200 mg loading dose and then the 50 mg dose, 30.6% reported satisfaction, compared with 14.5% in the placebo group that switched to 50 mg.

The proportion of people who were satisfied with the amount of hair growth was 30.9% in the 10 mg ritexitinib group, and 67.5% in the 200 mg loading dose followed by the 50 mg group and the 50 mg group. This proportion was 22.6% in the placebo group. Among those patients who switched from placebo to the 200 mg loading dose and then the 50 mg dose or the 50 mg dose, 29% and 16.1%, respectively, reported satisfaction. Satisfaction with hair growth quality was 32.7% in the 10 mg group and 65.8% in the 50 mg dose group after the 200 mg loading dose compared to 23.4% in the placebo group and 30.6% and 16.1% in the two placebo-treated groups.

Patients who received rituxitinib reported extremely high levels of satisfaction with hair growth compared with placebo. This is the first study to use placebo-controlled clinical data to demonstrate the impact of AA treatment on patient satisfaction, including overall satisfaction and satisfaction with hair quality and quantity. These results confirm the benefit of treating AA to patients.